WASHINGTON (Reuters) - The risk of a potentially fatal brain disorder with Biogen Idec Inc's multiple sclerosis drug Tysabri increases as patients receive more infusions, U.S. health officials warned ...
Tysabri (natalizumab) helps treat forms of multiple sclerosis and Crohn’s disease. The drug comes as an infusion solution. Tysabri is not safe to receive in pregnancy and may not be safe to receive ...
Add Yahoo as a preferred source to see more of our stories on Google. The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly ...
A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS ...
that affects the central nervous system. There are various types of MS. Several of these are characterized by inflammation and damage due to demyelination and scarring in the central nervous system, ...
TYSABRI is a well-established high-efficacy treatment that now provides two routes of administration enabling flexibility to meet patients' individual preferences and needs The subcutaneous option ...
April 22, 2011 — The natalizumab (Tysabri, Biogen Idec) label has been updated to further quantify the risk for progressive multifocal leukoencephalopathy (PML) in patients taking the drug. The new ...
This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. When Tysabri first came on the market in 2004 to treat multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results